Wei Guan1, Songlin Li2,3, Zhimin Zhang4, He Xiao1, Juan He1, Jian Li1, Xuan He1, Jia Luo1, Yun Liu1, Lin Lei1, Jungang Ma1, Lizhao Chen5, Chuan Chen1. 1. Department of Cancer Center, Daping Hospital, Army Medical University, Chongqing, China. 2. Cancer Center, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China. 3. Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China. 4. Cancer Center, Renmin Hospital of Wuhan University, Wuhan, Hubei, China. 5. Department of Neurosurgery, Daping Hospital, Army Medical University, Chongqing, China.
Abstract
BACKGROUND: The prognosis of thymic epithelial tumors (TETs) currently relies on the commonly adopted WHO classification and Masaoka staging system, which cannot reflect the undefined biological behaviors limiting them as prognostic factors. METHODS: In this study, we first identified 40 genes and 179 genes, respectively that were epigenetically upregulated and silenced, corresponding to a total of 509 functionally methylated CpG sites between thymomas and thymic carcinomas by using the TCGA dataset. RESULTS: The methylation β-values of cg20068620 in MAPK4 and cg18770944 in USP51 were significantly associated with recurrence-free survival (RFS). In the independent validation cohort, only WHO classification and methylation β-values of cg20068620 in MAPK4 were independent prognostic factors for RFS in Chinese patients with TETs. A linear weighted model including these two factors was used to calculate the recurrence risk score (RRS). Time-dependent ROC curve analysis revealed that RRS was overwhelmingly superior to WHO classification for predicting 3-, 5-, and 10-year RFS and Masaoka stage for 3- and 5-year RFS. CONCLUSIONS: These results suggested that the methylation site cg20068620 in MAPK4 can improve the accuracy of the WHO classification alone regarding the prognostic value of TETs recurrence.
BACKGROUND: The prognosis of thymic epithelial tumors (TETs) currently relies on the commonly adopted WHO classification and Masaoka staging system, which cannot reflect the undefined biological behaviors limiting them as prognostic factors. METHODS: In this study, we first identified 40 genes and 179 genes, respectively that were epigenetically upregulated and silenced, corresponding to a total of 509 functionally methylated CpG sites between thymomas and thymic carcinomas by using the TCGA dataset. RESULTS: The methylation β-values of cg20068620 in MAPK4 and cg18770944 in USP51 were significantly associated with recurrence-free survival (RFS). In the independent validation cohort, only WHO classification and methylation β-values of cg20068620 in MAPK4 were independent prognostic factors for RFS in Chinese patients with TETs. A linear weighted model including these two factors was used to calculate the recurrence risk score (RRS). Time-dependent ROC curve analysis revealed that RRS was overwhelmingly superior to WHO classification for predicting 3-, 5-, and 10-year RFS and Masaoka stage for 3- and 5-year RFS. CONCLUSIONS: These results suggested that the methylation site cg20068620 in MAPK4 can improve the accuracy of the WHO classification alone regarding the prognostic value of TETs recurrence.
Authors: Alexander Marx; John K C Chan; Jean-Michel Coindre; Frank Detterbeck; Nicolas Girard; Nancy L Harris; Elaine S Jaffe; Michael O Kurrer; Edith M Marom; Andre L Moreira; Kiyoshi Mukai; Attilio Orazi; Philipp Ströbel Journal: J Thorac Oncol Date: 2015-10 Impact factor: 15.609
Authors: Nicolas Girard; Ronglai Shen; Tianhua Guo; Maureen F Zakowski; Adriana Heguy; Gregory J Riely; James Huang; Christopher Lau; Alex E Lash; Marc Ladanyi; Agnes Viale; Cristina R Antonescu; William D Travis; Valerie W Rusch; Mark G Kris; William Pao Journal: Clin Cancer Res Date: 2009-10-27 Impact factor: 12.531
Authors: You Quan Li; Yun Ming Tian; Sze Huey Tan; Ming Zhu Liu; Grace Kusumawidjaja; Enya H W Ong; Chong Zhao; Terence W K Tan; Kam Weng Fong; Kiattisa Sommat; Yoke Lim Soong; Joseph T S Wee; Fei Han; Melvin L K Chua Journal: J Clin Oncol Date: 2018-02-07 Impact factor: 44.544